Virios Therapeutics, Inc. received notice from Nasdaq that it has been granted an exception until October 28, 2024 to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
AI Assistant
DOGWOOD THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.